Ann Transplant 2008; 13(1): 26-26 :: ID: 880180
Sirolimus (SRL) (rapamycine) and everolimus (RAD), 40-hydroxy-rapamycine, were recently introduced as proliferation signal inhibitors (PSI) immunosuppressants, acting on the mTOR (target of rapamycine) IL2 synthesis. Due to different development strategies, SRL was registered in renal transplantation with steroids and cyclosporine (CyA) for the first three months, whereas RAD both in renal and cardiac transplantation with steroids and (reduced doses) CyA. Therapeutic drug monitoring (TDM) was recommended to control the enhancement of CyA nephrotoxicity and document RAD therapeutic detectable levels. Target trough concentration range were defined respectively as 3-8 and 4-12 ng/mL for RAD and SRL, the latest increased after CyA withdrawal [12-20]. Dose regimen are 2-5 mg QD (SRL) and 0.75 mg BID (RAD), taking in account the inhibition of CyA on PSI metabolism. Security profile exhibited hyperlipidemia, haematotoxicity, and more specific side effects (interstitial pneumopathy, lymphoceles and mucositis). Pharmacokinetics particularities of these lipophilic drugs resulted in long half-lives, poor bioavailability, intensive metabolism and numerous pharmacokinetic CYP3A4 drug interactions. Interindividual variability appeared more important than intraindividual. PSI exhibited similar pharmacodynamics but RAD appeared easiest to manage in clinical practice, due to its reduced halflife (30 h) as compared to SRL (60 h). TDM is performed using LC-MS/MS, but immunoassays are available from Abbott (MEIA, SRL) and Seradyn (Innoï¬‚uor FPIA, RAD), exhibiting cross reactions (>80%) with metabolites and between PSI. International proficiency testing schemes are available (www.bioanalytics.uk). The place of these drugs in the immunosuppressive strategy has to be settled in the future, specially regarding delayed graft dysfunction prevention.
Keywords: Sirolimus, Everolimus, immunosuppressants
06 May 2022 : Original articlePhosphatidylethanol (PEth) for Monitoring Sobriety in Liver Transplant Candidates: Preliminary Results of D...
Ann Transplant In Press; DOI: 10.12659/AOT.936293
Most Viewed Current Articles
31 Dec 1969 : Original articleEfficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...
Ann Transplant 2021; 26:e933588
31 Dec 1969 : Review articleRecurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models
Ann Transplant 2022; 27:e934924
31 Dec 1969 : Review articleKidney Transplantation in the Times of COVID-19 – A Literature Review
Ann Transplant 2020; 25:e925755